Sun Pharmaceutical Industries Limited has informed the Exchange that Board of Directors at its meeting held on 22 May 2025, recommended Final Dividend of Rs. 5.50 per equity share.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty 100 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma's board met on 22 May 2025 and approved audited standalone and consolidated financial results for Q4 and FY25 (year ended 31 March 2025), with statutory auditors SRBC & Co LLP issuing an unmodified (clean) opinion. The board recommended a final dividend of Rs. 5.50 per equity share, taking total FY25 dividend to Rs. 16 per share (including the Rs. 10.50 interim dividend declared in January 2025); record date is 7 July 2025 and payment is due by 8 August 2025. On the numbers, standalone revenue from operations grew about 13.5% to Rs. 23,003 crore and standalone profit after tax jumped nearly 50% to Rs. 4,283 crore (FY24: Rs. 2,858 crore), with EPS rising to Rs. 17.8 from Rs. 11.9. The company also appointed Ms. Vidhi Shanghvi as Whole-time Director for 5 years, noted the retirement of non-executive director Mr. Sudhir Valia, appointed KJB & Co LLP as Secretarial Auditor for 5 years, and fixed the 33rd AGM for 31 July 2025.
Strong earnings growth, a healthy total dividend yield, and a clean audit opinion are positive signals for shareholders, while the exit of long-time director Sudhir Valia and entry of a Shanghvi family member as Whole-time Director are governance points investors may want to monitor. Non-current borrowings have been fully paid down, strengthening the balance sheet.